
Thanks to #UEG for the invitation to participate in the promo for our new exciting event UEGW 2020 Virtual! 🙌#UEGEdu @myUEG It´s going to be amazing! Tagging @RuiCastroHD @siaq82 See you soon! 🧙♂️

MD, PhD. Gastroenterology and IBD. Norwegian University of Science, NTNU #ECCO National Rep #UEG Education Committee @YOGI_IBD Founder Keen on original ideas!💡

Thanks to #UEG for the invitation to participate in the promo for our new exciting event UEGW 2020 Virtual! 🙌#UEGEdu @myUEG It´s going to be amazing! Tagging @RuiCastroHD @siaq82 See you soon! 🧙♂️

#MondayNightIBD 🎥series kicks off w/ @EdLoftus2 & @DCharabaty discussing #IBD RCTs (&🆓 #CME) x.com/i/broadcasts/2JQeRAqpJ…

Want to shape the future of GI education in Europe? 🎓 UEG is looking for 5 new Education Committee members (2027 – 2030) to help drive our educational activities and influence how gastroenterologists learn. Be part of it! Apply by Nov 27 👉 bit.ly/3PbezgA

🔥 🔥 Have a read of this fantastic new review looking at the role of Tumour necrosis factor-like cytokine 1A (TL1A) in IBD 🔥 🔥 TL1A drives intestinal inflammation and fibrosis, with several TL1A inhibitors showing promising phase 2 data and phase 3 trials underway. TL1A inhibition could expand future therapeutic options for IBD, potentially enabling more personalised treatment strategies 🤩 👏 Have a read of the full article ⬇️ bit.ly/3UsUo6U @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @dtleiberman @BSGtrainees @WorldGastroOrg @ulstergastro @AmCollegeGastro @Aegastro @SAGES_updates @WAGE_media #IBD #Crohns #UlcerativeColitis #Gastroenterology #GITwitter #GIresearch #Colitis #CCUK #MedTwitter #IBDLife #DigestiveHealth #IBDAwareness #PrecisionGI #TranslationalGI #Gastro #GastroX #IBDScience #GutHealth #ImmunologyMeetsGI #NextGenGastro

In your opinion/experience: What are the main barriers to enrolling pts in #IBD RCT ? 🗳️Tell us what you think👇🏽 📌 Nov 16 for a 🎥 convo with @EdwardLoftus2 sharing his 💭, 🔥upcoming RCTs to watch for- & how he approaches the RCT convo with his patients #MondayNightIBD
#IBDPoll1️⃣ 🆓CME👉🏼mnibd.short.gy/LoftusPost In your opinion/ experience, Which feature of the traditional RCT induction (drug vs PBO) + Re-randomize responders during maintenance- design mostly contributes to patient reluctance to enroll in RCT ?

Management of C diff infection in patients with IBD - AGA Clinical Practice Update 2026

Personalized therapies for Crohn's and ulcerative colitis may follow from method that identifies harmful gut bacteria medicalxpress.com/news/2026-…

🛑Before reducing upadacitinib to 30mg in UC, check for clinical and biochemical remission. These--not how long on 45mg--predict adverse outcomes ➡️Our practice: check PROs and FC at 6 weeks to guide dosing past 8wk 🥳to @sarah_rotondoMD and @rajdalalmed on this impactful work!
When is it safe to de-escalate upadacitinib from 45 mg in UC? In our newly published study, clinical and biochemical remission—not duration of induction—predicted successful dose de-escalation. Treat the patient, not the calendar. 🎯 Read more: doi.org/10.1093/crocol/otag1…

The paper is much more interesting than the title! There are many findings weaved into one scientific journey.

❇️ Fantastic thread! Thanks for breaking this landmark paper so nicely @IBDGastroDocSg 🙌🏻
Why do some UC patients fail vedolizumab (VDZ)? A landmark study in Nature Medicine by Schreiber et al. unpacks the biological mechanism of VDZ resistance: revealing an alternative vascular bypass that might be targetable with common medications

An “UC antibody” that shows up in Crohn's? 🧬 Anti-αvβ6 IgG was detected in pediatric CD, but almost entirely when the colon was involved. Disease label or disease location? 👀 doi.org/10.1002/jpn3.70444?u… #pediatrics #PedsGI #IBD

58% of us reflexively chose to escalate to q4w. When the #VERDICT trial data dropped at #UEGWeek, that was my exact first reaction too: “Here is randomized proof that stepping up the dose captures endoscopic remission.” But that isn't what VERDICT proved. 🧵👇
42yo with distal UC on standard maintenance vedolizumab (300 mg q8w). At Week 16: - Stool frequency: normal - Rectal bleeding: none - Sigmoidoscopy: Mayo 2 Following the recent #VERDICT trial data from #UEGWeek, what is your next move? @my_ueg @MondayNightIBD #IBD #GITwitter

What's new and interesting in IBD prevention and management? @YOGI_IBD is organizing this webinar on BEST OF @UegWeek in IBD 2026 📆 Wednesday, Nov 25 ⏰ 6 pm Norway/Spain 12 PM ET USA 👉 Register for free here: shorturl.at/xpybm

Kono-S in Crohn's ileocaecal resection (n=70, FMC & IBD SA), now in early access in Techniques in Coloproctology. Shorter stay and fewer ileostomies, but mostly explained by patient selection. Biologics, not technique, predicted 12-mo recurrence. Great work leading this @warren_seow doi.org/10.1007/s10151-026-0…

🧪 Perianal fistulas clear infliximab faster 📍 ATLANTIC: prospective PK cohort, 148 patients on standard IV infliximab 5 mg/kg (62 perianal fistulizing CD vs 86 luminal CD) 📈 +23% clearance in progressive perianal disease (TOpClass ≥2c) during induction 🎯 Week 14: only 9% of PFCD patients reached their target trough (≥10 µg/mL) vs 46% of luminal CD (≥5 µg/mL) 🩸 Median trough at week 14: 2.9 vs 4.8 µg/mL 💡 Authors' case: front-loaded induction plus early TDM in PFCD ⚠️ Single centre, PK study, different targets per phenotype. No RCT yet of intensified vs standard induction 👇 Key numbers in one image 🔗 doi.org/10.1093/ecco-jcc/jja… #MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #PerianalCrohns

BEST OF @UegWeek in IBD 2026 BARCELONA Wed Nov 25 6 pm Norway/Spain 12 PM ET USA Register🔗shorturl.at/xpybm Speakers: Marie Truyens (Belgium) @GianlucaPellino (Spain) Mohammad Malik (Kuwait) Moderators: Heba Al-Farhan (Kuwait);@ign76 (Norway) See you!